Triumph Capital Management’s Sinovac Biotech, Ltd SVA Stock Holding History

Triumph Capital Management’s Portfolio SVA Stock Details SVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14	Closed	–	–	1926
2026 Q1	$0	Buy	+14	New	–	﹤0.01%	1905

Other funds holding SVA

NAH

Neumann Advisory (HK) Central, Hong Kong $356M AUM 37.48% 1-Year Est. Return

Triumph Capital Management's SVA Position: Q2 2026 in Review

Triumph Capital Management sold out of Sinovac Biotech, Ltd (SVA) in Q2 2026, closing a stake of 14 shares.

Triumph Capital Management first reported a position in SVA in Q1 2026 and held it in 1 quarter. The position peaked at $0 in Q1 2026. 2 funds tracked by Wall St. Rank hold SVA as of Q2 2026.

Triumph Capital Management reported no remaining Sinovac Biotech, Ltd position as of Q2 2026 after selling out during the quarter.
Triumph Capital Management sold 14 Sinovac Biotech, Ltd shares in Q2 2026.
Triumph Capital Management first reported a position in Sinovac Biotech, Ltd in Q1 2026 and held it in 1 quarter.
Triumph Capital Management's Sinovac Biotech, Ltd position peaked at $0 in Q1 2026.
2 funds tracked by Wall St. Rank held Sinovac Biotech, Ltd as of Q2 2026.

Based on Triumph Capital Management's 13F filing for Q2 2026, filed 21 Jul 2026.